SAN DIEGO, June 22 /PRNewswire/ -- TheraLife(TM) Inc. today announced that
TheraLife(TM) Inc., has been selected to present at the "Bio 2001" conference
in San Diego on June 24-27, 2001. Dr. Lily Yang and Dr. Armin Ramel will be
presenting at the Technology Partnering Forum on June 26, 2001 from
2-5 p.m. as part of the Device, Delivery, and Diagnostics portion of the
conference.
TheraLife(TM) is a botanical drug company with a drug enhancement system
(DES) -- the TheraLife(TM) Enhancer. This technology is a multi-component
system that combines the benefits of faster, safer delivery with reduced side
effects
"There are many areas in which drug performance could be improved," says
Dr. Yang. These areas include insufficient solubility; toxicity; slow
pharmacokinetics (slow in getting into the blood stream); and molecules too
large for oral administered, which must be delivered via IV (intravenous) or
IM (intramuscular) injection.
Large molecules are broken down by enzymes in the stomach and gut,
rendering them no longer active. This is particularly true for
biopharmaceuticals, e.g., proteins, which are naturally occurring large
molecules. Insulin is such an example. It must be injected intramuscularly.
Diabetic patients need insulin daily, sometimes several times a day. There
are now companies delivering insulin by aerosol methods, i.e. producing small
droplets by spraying the drug into the lungs or buccal area (the mucosal area
in the back of the throat). However, the lung cells and buccal cells have
limited capacity for the absorption of the drug molecule.
There are many pharmaceutical compounds chemically designed to facilitate
absorption. In contrast, TheraLife(TM) Inc. (Los Altos, Calif.) has come up
with a unique multi-component formulation specifically designed to:
1) Increase cellular metabolism, therefore facilitating drug absorption;
2) Increase microcirculation, therefore reaching areas that have poor or
decreased circulation; 3) Protect kidney and liver cells. TheraLife(TM) is
positioned to leverage this technology to enhance drug absorption to be
faster, safer and with lower side effects.
To validate this drug enhancement system (DES), TheraLife(TM) completed a
Stage 1 double blind, placebo controlled clinical trial using a combination of
this technology with the TheraLife Eye specific formula for the treatment and
relief of "dry eyes." The eye has poor circulation and it is very difficult
for oral medications to reach it. The company plans to submit clinical trial
results to the FDA, establish medical claims, and develop corporate
partnerships for its marketing and distribution.
Notice: This release and oral statements made from time to time by
TheraLife(TM) representatives concerning the same subject matter may contain
so-called "forward-looking statements." These statements can be identified by
introductory words such as "expects," "plans," "will," "estimates,"
"forecasts," "projects," or words of similar meaning, and by the fact that
they do not relate strictly to historical or current facts. Forward-looking
statements frequently are used in discussing regulatory submissions and
approvals, development programs, etc. Many factors may cause actual results
to differ from forward-looking statements, including inaccurate assumptions
and a broad variety of risks and uncertainties, some of which are known and
others of which are not. No forward-looking statement is a guarantee of
future results or events, and one should avoid paying undue reliance on such
statements.
SOURCE TheraLife Inc.
 back to top
Related links:
http://www.theralife.com
CONTACT:
James Alston of TheraLife Inc., 650-917-1989,
or fax, 650-917-1434, or Jalston@theralife.com
|
